Literature DB >> 26706601

High VRK1 expression contributes to cell proliferation and survival in hepatocellular carcinoma.

Wei Huang1, Xiaopeng Cui2, Yuyan Chen3, Mengting Shao4, Xian Shao2, Yifen Shen4, Qingqing Liu1, Miaomiao Wu1, Jinxia Liu1, Wenkai Ni1, Cuihua Lu5, Chunhua Wan6.   

Abstract

VRK1 is a member of the vaccinia-related kinase (VRK) family of serine/threonine protein kinases, which is known to play multiple roles in cellular proliferation, cell cycle regulation and carcinogenesis. However, the expression and physiological significance of VRK1 in hepatocellular carcinoma (HCC) remain unclear. In this study, we aimed to investigate the potential role of VRK1 in the development and progression of HCC. Western blot and immunohistochemical analysis revealed that VRK1 was highly expressed in HCC tissues and cell lines, compared with adjacent nontumorous tissues and LO2 normal hepatocytes. Meanwhile, clinicopathological analysis showed that VRK1 was significantly associated with AJCC stage, Ki-67 and a poor prognosis in HCC specimens. Univariate and multivariate analysis showed that VRK1 could serve as an independent prognostic indicator of HCC patients' survival. Furthermore, we found that VRK1 was lowly expressed in serum-starved Huh7 cells, and was progressively increased after serum-refeeding. Finally, flow cytometry, CCK-8 and colony formation assay indicated that the depletion of VRK1 could retard cell cycle progression and reduce cells proliferation in HCC cells. On the basis of these findings, we conclude that VRK1 may be a candidate prognostic biomarker as well as a potential therapeutical target of HCC.
Copyright © 2015 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Cell proliferation; Hepatocellular carcinoma; Prognosis; VRK1

Mesh:

Substances:

Year:  2015        PMID: 26706601     DOI: 10.1016/j.prp.2015.11.015

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  8 in total

1.  4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.

Authors:  Gen Wang; Sisi Qin; Jacqueline Zayas; James N Ingle; Mohan Liu; Richard M Weinshilboum; Kunwei Shen; Liewei Wang
Journal:  Breast Cancer Res Treat       Date:  2019-04-01       Impact factor: 4.872

2.  VRK1 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis In Vitro and In Vivo.

Authors:  Jiacheng Wu; Tao Li; Hao Ji; Zhi Chen; Baoqian Zhai
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.810

3.  Potential role of microRNA‑223‑3p in the tumorigenesis of hepatocellular carcinoma: A comprehensive study based on data mining and bioinformatics.

Authors:  Rui Zhang; Li-Jie Zhang; Mei-Ling Yang; Lan-Shan Huang; Gang Chen; Zhen-Bo Feng
Journal:  Mol Med Rep       Date:  2017-11-27       Impact factor: 2.952

Review 4.  Implication of the VRK1 chromatin kinase in the signaling responses to DNA damage: a therapeutic target?

Authors:  Ignacio Campillo-Marcos; Pedro A Lazo
Journal:  Cell Mol Life Sci       Date:  2018-04-20       Impact factor: 9.261

5.  Continued poxvirus research: From foe to friend.

Authors:  Susanna R Bidgood
Journal:  PLoS Biol       Date:  2019-01-30       Impact factor: 8.029

6.  DNA Aptamers against Vaccinia-Related Kinase (VRK) 1 Block Proliferation in MCF7 Breast Cancer Cells.

Authors:  Rebeca Carrión-Marchante; Valerio Frezza; Ana Salgado-Figueroa; M Isabel Pérez-Morgado; M Elena Martín; Víctor M González
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-17

7.  Selenoprotein P inhibits cell proliferation and ROX production in HCC cells.

Authors:  Jianxin Wang; Pei Shen; Sha Liao; Lian Duan; Dandan Zhu; Jinling Chen; Liuting Chen; Xiaolei Sun; Yinong Duan
Journal:  PLoS One       Date:  2020-07-31       Impact factor: 3.240

8.  Overexpression of the VRK1 kinase, which is associated with breast cancer, induces a mesenchymal to epithelial transition in mammary epithelial cells.

Authors:  Aye M Mon; A Craig MacKinnon; Paula Traktman
Journal:  PLoS One       Date:  2018-09-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.